- Conditions
- Sleep Apnea, Sleep Disordered Breathing
- Interventions
- liraglutide
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus
- Interventions
- Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastrointestinal Symptoms, Weight Loss, GLP-1
- Interventions
- High Fiber Bar with Inulin, High Fiber bar with Fiber Blend, High Fiber Bar with Resistant Starch type 4, Low Fiber Bar
- Other
- Lead sponsor
- Midwest Center for Metabolic and Cardiovascular Research
- Other
- Eligibility
- 25 Years to 64 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Miami Gardens, Florida • Port Saint Lucie, Florida
- Conditions
- Alcohol Use Disorder (AUD)
- Interventions
- Pemvidutide, Placebo
- Drug · Other
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more
- Conditions
- Obesity, Overweight, or Chronic Weight Management
- Interventions
- Aleniglipron or Placebo, Aleniglipron
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
- Conditions
- Obesity, Childhood
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Heart Disease
- Interventions
- Exendin-9, GLP-1, saline
- Drug · Other
- Lead sponsor
- David Dalessio
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Type 1 Diabetes
- Interventions
- Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
- Interventions
- Not listed
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes
- Interventions
- Bi-homonal Bionic Pancreas, Usual care
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- GLP - 1
- Interventions
- Digital Lifestyle Coaching Program
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Insulin Resistance, Prediabetic State
- Interventions
- Metformin, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
- Interventions
- REMD-477, Placebo Subcutaneous injection
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
- Interventions
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
- Drug
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
- Conditions
- Lung Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity, Overweight
- Interventions
- KAI-7535, Placebo
- Drug
- Lead sponsor
- Kailera
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 31
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Irvine, California + 25 more
- Conditions
- Obesity
- Interventions
- Exenatide, Normal saline .2cc subcutaneous injection
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- SAR438544, placebo, r-glucagon
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Exendin (9-39), Vehicle
- Drug
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Interventions
- G-Pen, Novo Glucagon
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Walnut Creek, California • Atlanta, Georgia • Las Vegas, Nevada + 1 more
- Conditions
- Smoking Cessation, Weight, Body
- Interventions
- Liraglutide, Placebo, Smoking Cessation Counseling
- Drug · Behavioral
- Lead sponsor
- Rebecca Ashare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Obesity
- Interventions
- GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic)
- Drug · Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 1 Diabetes
- Interventions
- Glucagon-only Bionic Pancreas
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts